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A B S T R A C T
Objective: To evaluate the impact of eslicarbazepine acetate (ESL) monotherapy on markers of bone and lipid
metabolism.
Methods: We conducted a post-hoc analysis of data pooled from two Phase III, dose-blind, conversion-to-ESL
(1600mg and 1200mg) monotherapy studies in patients with focal seizures. Laboratory measurements included
lipids (total cholesterol [TC]; high-density lipoprotein cholesterol [HDL-C]; low-density lipoprotein cholesterol;
and triglycerides) and markers of bone metabolism (alkaline phosphatase; 25-hydroxyvitamin D; osteocalcin;
and parathyroid hormone [PTH]); measurements were taken at baseline, Week 18, and Month 12, and analyzed
according to enzyme-inducing antiepileptic drugs (EIAEDs) use at baseline (+EIAED and –EIAED subgroups).
Results: Data from 337 treatment-compliant patients were used for the Week 18 analyses (+EIAED subgroup,
n= 119; –EIAED subgroup, n= 218); data from 161 treatment-compliant patients were used for the Month 12
analyses (+EIAED subgroup, n= 53; –EIAED subgroup, n=108). At baseline, alkaline phosphatase and PTH
concentrations were higher in the+EIAED versus –EIAED subgroup. Changes from baseline in markers of bone
turnover were generally insignificant, except for some elevation in alkaline phosphatase in the –EIAED subgroup
(18 weeks and 12 months) and osteocalcin in both subgroups (18 weeks only). Regarding lipids, TC and HDL-C
concentrations were higher in the+ EIAED versus –EIAED subgroup at baseline. Concentrations of markers of
lipid metabolism fell in the+EIAED group and rose in the –EIAED group, reaching very similar values that were
intermediate between the –EIAED and+EIAED baseline values.
Conclusions: Based on this retrospective analysis, ESL seems to have had only a modest and primarily clinically
insignificant impact on plasma lipids. More prospective data are needed to definitively ascertain the effects of
ESL on bone metabolism.
1. Introduction
Carbamazepine (CBZ) has been a mainstay of epilepsy therapy since
its introduction 50 years ago. Like phenytoin (PHT) and phenobarbital,
however, its use is complicated by potent induction of the cytochrome
P450 (CYP450) enzyme system. This leads to a number of metabolic
effects, among them elevations in serum lipids (Bramswig et al., 2003;
Lopinto-Khoury and Mintzer, 2010) and alterations of bone metabolism
(Brodie et al., 2013; Mintzer, 2010). The related compound oxcarba-
zepine (OXC) was subsequently developed, and appears to share some,
though not all of the CYP450-inducing properties of CBZ; it does not
appear to affect serum lipids in the same manner (Isojarvi et al., 1994),
but it does have similar effects on bone metabolism (Mintzer et al.,
2006).
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The most recent entrant into the dibenzazepine carboxamide class
of drugs is eslicarbazepine acetate (ESL). ESL is an oral antiepileptic
drug (AED) approved for the treatment of focal (partial-onset) seizures
in patients ≥ 4 years of age. The approval of ESL was based, in part, on
two Phase III studies that used a conversion-to-monotherapy study
design (Jacobson et al., 2015; Sperling et al., 2015a).
Whether or not the induction of CYP450 by ESL leads to clinically
relevant effects remains to be established. Concomitant ESL treatment is
known to lower systemic exposure to simvastatin and, curiously, ro-
suvastatin (Gidal et al., 2017), which indicates that at least some en-
zymatic processes appear to be induced by the drug. A previous analysis
suggested that, when used as adjunctive therapy, ESL had only a modest
effect on serum lipids that was unlikely to be clinically meaningful
(Mintzer et al., 2018b). To date, there are no published data relevant to
the impact of ESL on bone metabolism.
We took advantage of the conversion-to-monotherapy design of the
two ESL studies and their 12-month open-label extension (OLE) to
perform a post-hoc analysis of the impact of ESL monotherapy on both
plasma lipids and markers of bone metabolism. We separated the po-
pulation into those switching from enzyme-inducing AEDs (EIAEDs) to
ESL, and those switching from non-enzyme-inducing AEDs to ESL.
2. Material and methods
2.1. Study design
Studies 093-045 (NCT00866775) (Sperling et al., 2015a) and 093-
046 (NCT01091662) (Jacobson et al., 2015) were randomized, dose-
blind, conversion-to-monotherapy studies. The two studies were iden-
tical, and have been described in full elsewhere, including the study
design, inclusion and exclusion criteria, and primary and secondary
endpoints (Jacobson et al., 2015; Sperling et al., 2016, 2015a). As de-
scribed by French et al., both studies used a historical control group for
evaluation of efficacy (French et al., 2010). The studies were conducted
in accordance with the principles of the Declaration of Helsinki, the
International Conference on Harmonisation guidelines, and all national,
state, and local laws of the pertinent regulatory authorities. Approval
was received from the relevant independent ethics committees/in-
stitutional review boards, and all patients provided informed consent.
Patients were aged 16–70 years with focal seizures not adequately
controlled by one or two AEDs (only one sodium channel blocker was
allowed). After an 8-week baseline period, patients were randomized in
a 2:1 ratio to receive 1600mg or 1200mg ESL once-daily (QD) for 18
weeks (a 2-week ESL titration period, followed by a 6-week AED con-
version period [other AEDs were withdrawn], and a 10-week ESL
monotherapy period).
At the end of the dose-blinded period, eligible patients could enter a
12-month OLE study, 093-050 (NCT00910247) (Sperling et al., 2015b)
during which they continued to receive open-label (OL) ESL. Doses
could be adjusted at the discretion of the investigators, between 800mg
QD and 2400mg QD, and patients were permitted to resume taking up
to two concomitant AEDs, excluding OXC (in this article we report data
from the OLE study only for those patients who continued to take ESL
without adding other AEDs).
2.2. Laboratory measurements
Laboratory measurements were conducted in non-fasting conditions
and included lipids (total cholesterol [TC]; high-density lipoprotein
cholesterol [HDL-C]; low-density lipoprotein cholesterol [LDL-C]; and
triglycerides) and markers of bone metabolism (alkaline phosphatase;
25-hydroxyvitamin D [25-OHD]; osteocalcin; and parathyroid hormone
[PTH]).
Plasma concentrations of specified markers were determined at
baseline, after 18 weeks of dose-blind treatment, and after 12 months of
OL treatment.
2.3. Analyses
Analyses of data from the dose-blind treatment period were con-
ducted for the pooled population of compliant patients. Analyses of
data from the OLE study were conducted for patients compliant for the
12-month OL period and who continued to take ESL monotherapy
without adding other AEDs, i.e., ‘true monotherapy’ patients. Patients
who took ≥ 70% of their ESL doses were deemed to be compliant.
Summary statistics were calculated for subgroups defined retro-
spectively on the basis of whether or not patients were taking EIAEDs
(CBZ or PHT) during the baseline periods of Studies 045 and 046. CBZ
and PHT were specified as EIAEDs for this analysis, as they were the
most frequently used EIAEDs in the two studies. The+EIAED subgroup
included patients taking an EIAED at baseline; the –EIAED subgroup
included patients not taking an EIAED at baseline.
Exploratory, post-hoc, nonparametric Wilcoxon signed-rank tests
were conducted to compare markers of lipid metabolism and bone
turnover between baseline and 18 weeks, and between baseline and 12
months (separately for the+EIAED and –EIAED groups), as it cannot
be assumed that the data were normally distributed. Fisher’s exact tests
were conducted to compare proportions of clinically meaningful
changes from baseline in lipid parameters between the+EIAED and
–EIAED groups at 18 weeks and 12 months.
3. Results
3.1. Patient demographics and baseline characteristics
3.1.1. Dose-blind treatment
Of the 365 patients who received at least one dose of ESL (1600mg
or 1200mg), 337 (92%) were treatment compliant. Of the compliant
patients, 119 (35%) were using an EIAED (CBZ or PHT) during the
baseline period (+EIAED subgroup) while 218 (65%) were not using an
EIAED during baseline (–EIAED subgroup). Median age (range) was 38
(16–68) years and 48% of patients were male.
3.1.2. Open-label treatment
A total of 274 patients entered the OLE study. By the cut-off date for
this analysis (March 21, 2014), 180 patients had completed a year of OL
treatment and 157 had completed a year of ESL monotherapy (without
reintroducing other AEDs); 161 patients were treatment compliant. Of
the compliant patients, 53 (33%) were in the+ EIAED subgroup and
108 (67%) were in the –EIAED subgroup.
In the+ EIAED subgroup, the most frequently used baseline AEDs
were CBZ (77%) and PHT (24%). Levetiracetam (34%), valproic acid
(27%), and lamotrigine (26%) were the most frequently used baseline
AEDs in the –EIAED subgroup.
Rates of use of concomitant medications with potential to alter
markers of bone turnover differed between the+ EIAED and –EIAED
subgroups with respect to bisphosphonates, calcium, and vitamin D
(when combined into a single group) and OXC (Table 1). OXC was used
by 10% of patients in the –EIAED subgroup and 1% in the+ EIAED
subgroup, while bisphosphonates, calcium, or vitamin D were used by
22% of patients in the –EIAED subgroup and 11% in the+ EIAED
subgroup.
3.2. Markers of bone turnover
At baseline, mean alkaline phosphatase (p= 0.000) and para-
thyroid hormone (p= 0.022) concentrations were higher in the
+EIAED subgroup than the –EIAED subgroup, while 25-OHD and os-
teocalcin were not different (p > 0.05; Fig. 1). After conversion to ESL
monotherapy, changes at both 18 weeks and 12 months were primarily
associated with p-values> 0.05, except for some elevation of alkaline
phosphatase in the –EIAED subgroup after switch, consistent with some
degree of enzyme induction (Fig. 1). In addition, there was an increase
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in osteocalcin between baseline and 18 weeks (but not 12 months) in
both the –EIAED and+EIAED subgroups, also potentially consistent
with some degree of enzyme induction.
3.3. Markers of lipid metabolism
At baseline, concentrations of all evaluated markers of lipid meta-
bolism were higher in the+EIAED subgroup than the –EIAED sub-
group, with p-values< 0.05 for TC (p= 0.002) and HDL-C (p=
0.016) (Fig. 2). After 18 weeks and 12 months of ESL monotherapy,
concentrations of all lipid markers fell in the+ EIAED group and rose in
the –EIAED group; TC concentrations reached very similar mean values
that were intermediate between the –EIAED (188.5mg/dL)
and+EIAED (206.4mg/dL) baseline values (Fig. 2). P-values were<
0.05 for the majority of cholesterol measures (though not for trigly-
cerides, or for LDL-C in the+ EIAED subgroup).
Table 1
Baseline use of medications with known potential to alter markers of bone
turnover, according to use of EIAEDs at baselinea.
Concomitant drug, n (%) –EIAED n=218 +EIAED n=119
Bisphosphonates 2 (0.9) 1 (0.8)
Calcium 24 (11.0) 9 (7.6)
Vitamin D 24 (11.0) 8 (6.7)
Bisphosphonates, or calcium, or Vitamin
D
48 (22.0) 13 (11.0)
OXC 21 (9.6) 1 (0.8)
Statinsb 27 (12.4) 12 (10.1)
–EIAED/+EIAED, patients not taking/taking EIAEDs during baseline; OXC,
oxcarbazepine.
Data are numbers and percentages of patients in each subgroup of the dose-
blind studies who were taking medications of each type during baseline (only
medications with known potential to alter markers of bone turnover are listed).
a Compliant patients only i.e., those who took ≥ 70% of their ESL doses.
b Simvastatin, atorvastatin, pravastatin, rosuvastatin, lovastatin, or fluvas-
tatin.
Fig. 1. Markers of bone turnover at baseline and after 18 weeks and 12 months of ESL monotherapy, according to use of EIAEDs at baseline.
The division between the top and bottom of the box represents the median value (i.e., the 50th quartile) and the yellow dot represents the mean value; the top of the
box represents the 75th quartile, and the bottom of the box the 25th quartile. The upper and lower ends of the whisker represent the maximum and minimum values,
respectively (excluding outliers). Values < Q1 – 1.5x IQR or > Q3+1.5x IQR were considered outliers (Q1 is the 25th quartile, Q3 is the 75th quartile, and
IQR=Q3 – Q1); values ranged from 5.1 to 95.6% for alkaline phosphatase, 4–83 ng/mL for 25-OHD, 3.0–95.2 ng/mL for osteocalcin, and 0.3–13.7 ng/dL for PTH.
BL data are the last non-missing values prior to initiation of study medication.
Patients receiving OL treatment did not take other AEDs.
P-values were calculated using the Wilcoxon signed-rank test to test whether the difference in values between baseline and each visit (18 weeks or 12 months) was
equal to 0 in the –EIAED or+ EIAED subgroups, and to test whether mean baseline values differed between the –EIAED or+ EIAED subgroups (all p-values are
nominal, being uncorrected for multiplicity).
25-OHD, 25-hydroxyvitamin D; BL, baseline; +EIAED, taking enzyme-inducing antiepileptic drugs during baseline; –EIAED, not taking enzyme-inducing anti-
epileptic drugs during baseline; ESL, eslicarbazepine acetate; IQR, interquartile range; OL, open-label; PTH, parathyroid hormone; Q, quartile.
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4. Discussion
The chief finding of this investigation is that plasma lipids fell when
patients were converted from EIAEDs to ESL, but rose in those con-
verted from non-inducing AEDs to ESL. This suggests that at the doses
tested, the enzyme-inducing effect of ESL may differ from that of the
AEDs to which patients were exposed at baseline.
Changes from baseline in cholesterol and its fractions were largely
associated with p-values< 0.05. The fact that this was not the case for
triglycerides may well be a function of the substantial variability of this
measure, a factor also seen in other studies (Nishiyama et al., 2019). In
addition, these measurements were made non-fasting; recent evidence
indicates that this has minimal impact on cholesterol measures, but it
can certainly affect triglycerides (Dyce, 2018; Nordestgaard, 2017).
Assessing the clinical significance for these data is interesting. It is
perhaps instructive to view each of the lipid measures as a three-way
comparison: the baseline value in the non-inducing AED group,
presumably reflecting the ‘normal’ state of patients’ cholesterol pro-
duction; the baseline value in the+ EIAED group, presumably re-
flecting the effect of full-fledged inducers; and the value (for either
group) after being switched to 1200/1600mg ESL monotherapy, pre-
sumably reflecting the impact of the latter drug. The fact that the post-
baseline values were so similar in the two groups reinforces the utility
of this comparison. Thus, for TC, one might infer that a mean baseline
value of 188mg/dL (non-inducer) was increased by about 18mg/dL
with the use of CBZ or PHT (to 206mg/dL, the baseline+EIAED value;
Fig. 2); this is consistent with prior work (Bramswig et al., 2003;
Mantel-Teeuwisse et al., 2001; Mintzer, 2010; Yilmaz et al., 2001).
With ESL, it increased only by about 7mg/dL (to 195mg/dL, the 12
month value in the –EIAED subgroup). While the effect of ESL on TC
was consistent enough to yield a p-value<0.05, this is clearly not a
large enough effect to be considered clinically meaningful. This is quite
similar to what was seen in an investigation of lipids in the ESL ad-
junctive studies (Mintzer et al., 2018b). Overall, our findings here,
Fig. 2. Markers of lipid metabolism at baseline and after 18 weeks and 12 months of ESL monotherapy, according to use of EIAEDs at baseline.
The division between the top and bottom of the box represents the median value (i.e., the 50th quartile) and the yellow dot represents the mean value; the top of the
box represents the 75th quartile, and the bottom of the box the 25th quartile. The upper and lower ends of the whisker represent the maximum and minimum values,
respectively (excluding outliers). Values < Q1 – 1.5x IQR or > Q3+1.5x IQR were considered outliers (Q1 is the 25th quartile, Q3 is the 75th quartile, and
IQR=Q3 – Q1); values ranged from 90 to 444mg/dL for TC, 14–153mg/dL for HDL-C, 31–328mg/dL for LDL-C, and 33–2081mg/dL for triglycerides.
BL data are the last non-missing values prior to initiation of study medication.
Patients receiving OL treatment did not take other AEDs.
P-values were calculated using the Wilcoxon signed-rank test to test whether the difference in values between baseline and each visit (18 weeks or 12 months) was
equal to 0 in the –EIAED or+ EIAED subgroups, and to test whether mean baseline values differed between the –EIAED or+ EIAED subgroups (all p-values are
nominal, being uncorrected for multiplicity).
BL, baseline; +EIAED, taking enzyme-inducing antiepileptic drugs during baseline; –EIAED, not taking enzyme-inducing antiepileptic drugs during baseline; ESL,
eslicarbazepine acetate; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; OL, open-label; Q, quartile;
TC, total cholesterol.
S. Mintzer, et al. Epilepsy Research 158 (2019) 106216
4
reinforced by the prior study, suggest that ESL did not have a clinically
important impact upon plasma lipids in the majority of patients.
Our findings with respect to bone metabolism are less clear. The
lack of significant change in bone metabolic markers may simply in-
dicate that ESL has little or no meaningful effect on these. However, the
baseline data, before the switch to ESL, are themselves unusual in that
there was no difference in 25-OHD between the two groups, despite a
large body of evidence indicating that CBZ can reduce 25-OHD sub-
stantially (Mintzer, 2010; Mintzer et al., 2006). This makes it difficult to
interpret the lack of change in 25-OHD levels subsequent to the switch
to ESL. The reason for the lack of baseline difference in this measure is
unclear; it is not likely to be related to Vitamin D supplementation, nor
to calcium supplementation, since this was seen at comparable rates in
both groups.
With regard to the bone turnover markers, the raw numbers in the
–EIAED subgroups for both alkaline phosphatase and PTH settled at
values similar to the+EIAED baseline after 12 months of switching to
ESL; however, the increase from baseline was associated with a p-
value<0.05 only for alkaline phosphatase. This suggests the possibi-
lity that ESL might increase bone turnover; however, the p-value as-
sociated with changes from baseline in PTH was> 0.05 and there was
no difference between osteocalcin and 25-OHD at baseline, making this
far from clear. More prospective work needs to be done to clarify the
impact of ESL on bone metabolism.
There are a number of limitations of this work. As is typical for a
post-hoc analysis, there were several potentially important factors for
which we could not entirely account. With respect to lipids, some pa-
tients were also taking 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (–EIAED subgroup, 12%; +EIAED subgroup,
10%). However, the lipid-lowering effect of these agents also appears to
be impacted by EIAEDs (Gidal et al., 2009; Mintzer et al., 2018a) and
not by ESL (which appears to have only a pharmacokinetic, not a
pharmacodynamic, interaction with HMG-CoA reductase inhibitors)
(Gidal et al., 2017; Mintzer et al., 2018b), so that one would expect the
same direction of lipid changes when EIAEDs are replaced by ESL. The
similarity of our lipid data to other published work also suggests that
this may not have been a major factor in our findings. Having obtained
our measurements in the non-fasting state makes the triglyceride data
less reliable. Regarding the bone markers, the fact that some patients
were supplementing with bisphosphonates, calcium, or Vitamin D is a
potential confounder, and more patients were taking these con-
comitants in the –EIAED subgroup than in the+ EIAED subgroup. OXC
was also used in more patients in the –EIAED versus the+ EIAED
subgroup. We were also unable to ascertain menopausal status for the
female subjects, which could certainly have impacted bone metabolism,
and did not adjust to account for patients taking oral contraceptives.
However, we do not believe that oral contraceptives have sufficient
impact on bone metabolism to have substantially affected the results
(Tremollieres, 2013).
An important limitation to this analysis is that Wilcoxon signed-rank
tests were neither pre-planned nor adjusted for multiplicity, and thus
the calculated p-values are nominal only. In addition, although p-va-
lues< 0.05 are widely used to measure statistical significance in
medical literature, they should not be over-interpreted in this manu-
script. Differences with p-values< 0.05 were more frequent in the
–EIAED subgroup than in the+ EIAED subgroup, likely because there
were almost twice the number of patients in the former. For a given
observed difference, a bigger sample size tends to be associated with a
smaller p value, because the p-value is, in part, a function of sample
size. For example, in the –EIAED group, differences in LDL-C between
baseline (104mg/dL) and 18 weeks (105mg/dL), as well as 12 months
(103.5 mg/dL), were associated with p-values< 0.01 (Fig. 2). By
comparison, in the+EIAED group, differences between baseline
(110mg/dL) and 18 weeks (101mg/dL), as well as 12 months (103mg/
dL), were associated with p-values higher than 0.05, even though dif-
ferences were numerically higher in the+EIAED group (Fig. 2). A
clinically meaningful difference may not be statistically significant at
the 5% level due to a small sample size; the reverse could also be true.
In summary, based on this retrospective analysis, ESL seems to have
had only a modest and primarily clinically insignificant impact on
plasma lipids. More prospective data are needed to definitively ascer-
tain the effects of ESL on bone metabolism.
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